Andrei A. Lazarev

Andrei A. Lazarev

Auto-generated profile, based on publicly available information

Andrei A. Lazarev

Bonch-Bruevich Saint Petersburg State University of Telecommunications

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2023 in Fundamental and Clinical Medicine
Verified
Journal Article
Open access
PDF file
AKA. A. Kuzin
A. A. Kuzin
RGRuslan ivanovich Glushakov
Ruslan ivanovich Glushakov
SPS. A. Parfenov
S. A. Parfenov
KSKirill V. Sapozhnikov
Kirill V. Sapozhnikov
ALA. A. Lazarev
A. A. Lazarev
Aim. Here, we provided an overview of artificial intelligence (AI) approaches for developing a system for prediction of infectious diseases and designed a respective step-by-step protocol.Materials and Methods. Literature search in PubMed and Google Scholar and PubMed.Key Points. Infectious diseases impose a heavy burden on a healthcare, demanding the development of novel and efficient approaches to prevention as well as sensitive and specific diagnostic tests. Evolution of data science have led to the emergence of promising artificial intelligence (AI) algorithms and tools for the forecasting of infectious diseases. Employing machine learning algorithms, AI systems can rapidly analyze a large amount of data, extract specific disease patterns, and screen for the most efficient AI instruments in relation to specific tasks, thus contributing to prevention, diagnostics, and treatment of infectious diseases in the context of personalized medicine. Importantly, such AI-based systems can determine specific human motor patterns from videos and/or photographs in order to assist physicians in primary diagnosis. Integration of AI tools into the existing healthcare algorithms can be especially useful for public health.

23 August 2025 in Neurology, Neuropsychiatry, Psychosomatics
Verified
Journal Article
Open access
PDF file
ABAlexey Boyko
Alexey Boyko
MZMariya N. Zakharova
Mariya N. Zakharova
TST. O. Simaniv
T. O. Simaniv
VAV. M. Alifirova
V. M. Alifirova
EAE. G. Arefieva
E. G. Arefieva
AZA. V. Zinkina-Orikhan
A. V. Zinkina-Orikhan
Objective: the aim of the AQUARELLE trial was to evaluate the efficacy of divozilimab compared with a historical control (placebo) and to characterise its safety in patients with neuromyelitis optica spectrum disorder (NMOSD).Material and methods. The AQUARELLE clinical trial population included patients aged 18 years and older with a diagnosis of NMOSD established in accordance with the international consensus diagnostic criteria for NMOSD (2015). The primary efficacy endpoint was the mean annual rate of confirmed exacerbations (MAR) over 6 months of treatment with divozilimab compared with a historical control, which was the placebo from the N-MOmentum study.Results. A total of 105 patients received treatment with the investigational drug divozilimab. At the time of analysis, the proportion of patients without confirmed exacerbations was 94.3% (99/105); the ARR was 0.124 (95% CI 0.056–0.276). The ARR ratio for divozilimab /historical placebo was 0.172 (90% CI 0,083–0,359), indicating the superiority of divozilimab compared to historical placebo over 6 months of therapy. During divozilimab therapy, a therapy-related decrease in lymphocyte count was reported in 16 (15.2%) patients, and infusion reactions were reported in 6 (5.7%) patients. The overall incidence of therapy-related infectious events was 6 cases (5.7%).Conclusion. Within patients with NMOSD, the use of divozilimab reduces the risk of exacerbations. The good tolerability of the drug allows divozilimab to be recommended as a new therapeutic option for patients with NMOSD.

6 March 2025 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
MZMariya N. Zakharova
Mariya N. Zakharova
TST.O. Simaniv
T.O. Simaniv
KSKirill V. Sapozhnikov
Kirill V. Sapozhnikov
DTD.G. Tolkacheva
D.G. Tolkacheva
VSV.D. Sokolova
V.D. Sokolova
TKT.V. Khimich
T.V. Khimich
Objective. To compare efficacy of the new drug divozilimab with other second-line treatment options for relapsing remitting multiple sclerosis (RRMS) that have been already included or submitted application to be included into the «14 high-cost nosologies» program in the Russian Federation. Material and methods. We conducted systematic literature review (PROSPERO ID CRD42022310082) and frequentist network meta-analysis of 2-years efficacy of divozilimab and other second-line therapies to treat RRMS. Results. Annualized relapse rate ratio in divozilimab vs fingolimod was 0.4 (95% CI 0.3—0.7), divozilimab vs cladribin 0.5 (95% CI 0.3—0.9), divozilimab vs alemtuzumab 0.7 (95% CI 0.3—1.7), divozilimab vs ocrelizumab 0.7 (95% CI 0.3—1.6), divozilimab vs ofatumumab 0.7 (95% CI 0.4—1.1), divozilimab vs natalizumab 0.4 (95% CI 0.4—1.1) respectively. Divozilimab had the highest SUCRA rank (0.9) while fingolimod had the lowest (0.4). Conclusion. Systematic literature review and network meta-analysis revealed statistically significant superiority of divozilimab over cladribine and fingolimod and absence of statistically significant differences with alemtuzumab, ocrelizumab, ofatumumab and natalizumab in the annual relapse rate during 2 years of treatment.

5 December 2025 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
AFAlexander A. Fedenko
Alexander A. Fedenko
MSMariya V. Sedova
Mariya V. Sedova
AKAlina A. Kolomeytseva
Alina A. Kolomeytseva
MBMaxim Batov
Maxim Batov
OMOlga N. Mironenko
Olga N. Mironenko
ISIgor Samoylenko
Igor Samoylenko
Background. Metastatic and unresectable melanoma is considered as one of the most aggressive oncological diseases with a high mortality rate. In Russia, two first line immunotherapy combinations have been approved: nivolumab plus ipilimumab (NIVO+IPI) and prolgolimab plus nurulimab (PROLGO+NURU). Both regimens use dual immune checkpoint blockade targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). However, the lack of direct randomized comparisons between these regimens makes it difficult to choose the optimal first-line therapy. Aim. This analysis evaluated the relative efficacy and safety of PROLGO+NURU versus NIVO 1 mg/kg + IPI 3 mg/kg (NIVO 1 + IPI 3) and NIVO 3 mg/kg + IPI 1 mg/kg (NIVO 3 + IPI 1) in patients with metastatic and unresectable melanoma using matching-adjusted indirect comparisons (MAICs). Materials and methods. A systematic literature review was performed in Embase and PubMed databases. Three phase III randomized controlled trials (RCTs) were included: OCTAVA (PROLGO+NURU, n=135), CheckMate 067 (NIVO 1 mg/kg + IPI 3 mg/kg, n=314), and CheckMate 511 (two regimens: NIVO 1 mg/kg + IPI 3 mg/kg, n=178; NIVO 3 mg/kg + IPI 1 mg/kg, n=180). Individual patient data (IPD) on outcomes and baseline characteristics for PROLGO+NURU were obtained from the OCTAVA trial. For the NIVO + IPI arms, IPD on overall survival (OS) and progression-free survival (PFS) were reconstructed using Guyot’s algorithm from the published Kaplan–Meier curves, and aggregated baseline-characteristic data were extracted. Pairwise unanchored MAICs were performed, weighting on key prognostic factors and effect modifiers: baseline lactate dehydrogenase levels, TNM-defined presence of distant metastasis (M-stage), Eastern Cooperative Oncology Group (ECOG) performance status, BRAF-mutation status, PD-L1 expression 5%, age, and sum of longest diameters of target lesions. To address partial population non-overlap – specifically, the absence of mucosal melanoma and of asymptomatic central-nervous-system metastases (after local control) in OCTAVA – a simulation-based modelling was applied. Efficacy outcomes were analyzed with Cox proportional-hazards regression, and safety outcomes with logistic regression. Results. OS was statistically significantly higher in the PROLGO+NURU arm than in either NIVO 1 + IPI 3 or NIVO 3 + IPI 1 arms: hazard ratio (HR) 0.69 (95% CI 0.47–0.96; p=0.026) in the CheckMate 067 population, HR 0.64 (0.42–0.91; p=0.011) and HR 0.63 (0.41–0.89; p=0.008) – in the CheckMate 511 population versus NIVO 1 + IPI 3 and NIVO 3 + IPI 1 regimens, respectively. Differences in PFS were statistically insignificant. The PROLGO+NURU regimen also demonstrated a more favorable safety profile, with a lower incidence of treatment-related adverse events, including Grade 3–4 events and events led to treatment discontinuation. Conclusion. MAICs results showed that the PROLGO+NURU regimen achieved statistically significant superiority in OS compared with the approved NIVO+IPI regimens in Russia (as of 2025). The PROLGO+NURU combination also displayed a more favorable safety profile, with fewer treatment-related adverse events, including Grade 3–4 events and events led to treatment discontinuation. It should be emphasized that the comparison is indirect and the horizon of the comparison was limited (by about 50 months in CheckMate 511 population and 65 months in CheckMate 067 population). Consequently, the findings should be interpreted cautiously. Further updates incorporating data for the longer follow-up, including real-world data, are recommended.

30 July 2025 in Real-World Data & Evidence
Verified
Journal Article
Open access
PDF file
ALAleksandr M Lila
Aleksandr M Lila
MKMaksim Korolev
Maksim Korolev
ISI. N. Shchendrigin
I. N. Shchendrigin
KSKirill V. Sapozhnikov
Kirill V. Sapozhnikov
ALA. A. Lazarev
A. A. Lazarev
DTD. G. Tolkacheva
D. G. Tolkacheva
   Background. Immunoinflammatory rheumatic diseases (IIRDs) are a significant medical and social problem leading to high mortality, disability and economic burden for society. These diseases, such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondylitis (axSpA), significantly reduce the quality of life of patients and increase the financial burden on healthcare systems.   Objective. The aim of this systematic review is to assess current data on the risk of death in patients with IIRDs and identify factors associated with increased mortality, as well as analyze the effectiveness of biological drugs in reducing this risk.   Materials and methods. The review includes data from multiple clinical trials and meta-analyses covering the period from 2000 to 2021. The analysis was based on data collected from various sources, including national registries, clinical trials and meta-analyses.   Results. The main results show that IIRDs such as RA, PsA and axSpA significantly increase the risk of death compared to the general population (SMR 2.02 1.79; 2.29). Disease activity, smoking and comorbid conditions are key factors increasing the risk of mortality. The use of biological agents in therapy reduces the risk of death compared to no biological therapy(HR 0.52 0.32; 0.86) and compared to methotrexate (HR 0.77 0.60; 0.97). The use of biological agents also reduces the risk of cardiovascular events and the development of dementia.   Conclusions. Early and active use of biological agents can be a significant factor in reducing the negative consequences of IRDs, including mortality and the progression of cardiovascular diseases.   Conclusion. The results of the systematic review may be useful for developing strategies for managing IIRDs and optimizing medical care for patients. The introduction of GIBPs into the treatment of IIRDs can significantly improve the prognosis and quality of life of patients, reducing the risk of mortality and other adverse outcomes.

6 September 2024 in Bulletin of the Russian Military Medical Academy
Verified
Journal Article
Closed access
PDF file
KSKirill V. Sapozhnikov
Kirill V. Sapozhnikov
SPSergei A. Parfenov
Sergei A. Parfenov
ALAndrei A. Lazarev
Andrei A. Lazarev
RKRuslan Kirichek
Ruslan Kirichek
DTDaria G. Tolkacheva
Daria G. Tolkacheva
VKValeriy V. Kulishenko
Valeriy V. Kulishenko
The study presented the main aspects of conducting Bayesian network meta-analysis as a method of indirect comparisons using mathematical models. To describe the performance of the Bayesian network meta-analysis, codes for the random-effects and fixed-effects models were included. The models were written in Component Pascal and run in the JAGS program. To allow cross-reference of results, data used for modeling purposes were generated data from the article by D. Hu, A.M. O'Connor, S. Wang et al. [6]. The R language and rjags package were used to load data into the model and run the program. To determine the best model, model adequacy indicators were used, such as total residual deviation, and leverage and deviation information criterion were calculated using the original R code. A graphical method was also used to determine the adequacy of the models using the ggplot2 package. An example of constructing a network of evidence based on available results on the effectiveness of drugs from clinical trials was considered, taking into account the assumptions of transitivity and heterogeneity. Indirect and direct comparisons to determine the true estimates of drugs were possible. The elements of Bayesian statistics, such as prior and posterior probabilities and likelihood, and the advantages of using them in meta-analysis were explained. The mathematical apparatus of the generalized linear model was presented in both general and specific forms, using binomial output data to obtain relative estimates of the effects of therapies. An explanation of how the models work is presented. The random-effects model showed superiority over the fixed-effects model in the comparison of adequacy metrics. To achieve better adequacy, data must be carefully downloaded from publications, and informative priors selected. In general, Bayesian synthesis is a distinct and important type of network meta-analysis. It is unique because it uses a probabilistic approach to data analysis. Understanding the basic principles of Bayesian statistics is also an important aspect of the successful use of this method in various research fields. However, for effective application of this method, attention must be paid to careful data preparation and the choice of priors. With informative prior distributions and proper implementation, Bayesian synthesis can produce more accurate and reliable results than other meta-analysis methods. Bayesian synthesis is a method of statistical data analysis recognized worldwide and in the Russian Federation..